Loading patent…
AssigneeHarbin Sunflower Pharmaceutical Co., Ltd.
InventorYanbin Guan
Estimating the term…
The present disclosure provides a Bifidobacterium lactis (B. lactis) strain XLTG11 and a use thereof. The strain belongs to Bifidobacterium lactis. The B. lactis strain XLTG11 was deposited in the China General Microbiological Culture Collection Center (CGMCC) on Oct. 25, 2019, with a taxonomic name of Bifidobacterium lactis XLTG11 and an accession number of CGMCC No. 18738. The B. lactis strain XLTG11 provided by the present disclosure can regulate an inflammatory cytokine, improve an intestinal barrier function, and modulate an intestinal flora by inhibiting the activation of a TLR4/MYD88/NF-κB signaling pathway, thereby alleviating dextran sulfate sodium (DSS)-induced colitis. In addition, the B. lactis strain XLTG11 has an immune-enhancing effect on a cyclophosphamide (CTX)-induced mouse immunosuppression model.
A method for preventing and/or alleviating colitis, comprising administering to a subject a product comprising a Bifidobacterium lactis strain XLTG11 having an accession number of CGMCC No. 18738 in an effective amount.
A method for modulating an intestinal flora, comprising administering to a subject a product comprising a Bifidobacterium lactis strain XLTG11 having an accession number of CGMCC No. 18738 in an effective amount.
A method for inhibiting an activation of a TLR4/MYD88/NF-κB signaling pathway, comprising administering to a subject a product comprising a Bifidobacterium lactis strain XLTG11 having an accession number of CGMCC No. 18738 in an effective amount.
A method for enhancing an immune function, comprising administering to a subject a product comprising a Bifidobacterium lactis strain XLTG11 having an accession number of CGMCC No. 18738 in an effective amount.
Dependencies are inferred from the claim text.